Q3 2019
2019 Q3 results - Tuesday, October 22, 2019
Media release
Interim financial report (PDF 0.8 MB)
Read the presentation transcript
Download the podcast (MP3 40 MB)
Download the presentation (PDF 2.3 MB)
| Continuing operations2 | |||
| Key figures1 | Q3 2019 (USD m) |
Q3 2018 (USD m) |
% change (USD/cc) |
|---|---|---|---|
| Net sales | 12,172 | 11,016 | 10 (cc: 13) |
| Operating income | 2,358 | 2,239 | 5 (cc: 9) |
| Net income | 2,041 | 1,882 | 8 (cc: 12) |
| EPS (USD) | 0.90 | 0.81 | 11 (cc: 14) |
| Free cash flow | 3,968 | 3,156 | 26 |
Core |
|||
| Operating income | 3,748 | 3,258 | 15 (cc: 18) |
| Net income | 3,212 | 2,820 | 14 (cc: 17) |
| EPS (USD) | 1.41 | 1.22 | 16 (cc: 19) |
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 56 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
- Refers to continuing operations as defined on page 44 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions.